ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100. The Company's CMX157 is a lipid acyclic nucleoside phosphonate that delivers intracellular concentrations of the active antiviral agent tenofovir diphosphate. The Company has completed a Phase I clinical trial of CMX157. The Company's CRV431 drug candidate is designed to target cyclophilins, which are a class of proteins. CRV431 inhibits the role of host cyclophilins and interferes in the propagation of the viruses. The Company's FV-100 is an orally available, small molecule, nucleoside analogue pro-drug of CF-1743, which is used for the treatment of herpes zoster. It has developed FV-100 for the treatment of shingles.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NASDAQ:CTRV
- CUSIP: N/A
- Web: www.contravir.com
- Market Cap: $42.68 million
- Outstanding Shares: 63,707,000
- 50 Day Moving Avg: $1.06
- 200 Day Moving Avg: $1.49
- 52 Week Range: $0.60 - $2.65
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.81
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: ($0.02) per share
- Price / Book: -33.50
- EBIDTA: ($21,360,000.00)
- Return on Assets: -198.05%
- Current Ratio: 0.70%
- Quick Ratio: 0.70%
- Average Volume: 1.32 million shs.
- Beta: 2.61
- Short Ratio: 3.51
Frequently Asked Questions for ContraVir Pharmaceuticals (NASDAQ:CTRV)
What is ContraVir Pharmaceuticals' stock symbol?
ContraVir Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTRV."
How were ContraVir Pharmaceuticals' earnings last quarter?
ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) posted its quarterly earnings data on Friday, May, 13th. The company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.09. View ContraVir Pharmaceuticals' Earnings History.
Where is ContraVir Pharmaceuticals' stock going? Where will ContraVir Pharmaceuticals' stock price be in 2017?
3 brokerages have issued 1 year price objectives for ContraVir Pharmaceuticals' stock. Their predictions range from $4.00 to $4.00. On average, they expect ContraVir Pharmaceuticals' share price to reach $4.00 in the next twelve months. View Analyst Ratings for ContraVir Pharmaceuticals.
Are investors shorting ContraVir Pharmaceuticals?
ContraVir Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totalling 4,954,852 shares, an increase of 41.3% from the April 28th total of 3,506,643 shares. Based on an average daily volume of 1,662,085 shares, the days-to-cover ratio is presently 3.0 days. Approximately 7.0% of the shares of the company are short sold.
Who are some of ContraVir Pharmaceuticals' key competitors?
Some companies that are related to ContraVir Pharmaceuticals include Mirati Therapeutics (MRTX), pSivida Corp. (PSDV), ArQule (ARQL), Microbot Medical (MBOT), aTyr Pharma (LIFE), Digirad (DRAD), Galectin Therapeutics (GALT), BIOLASE (BIOL), Novan (NOVN), Actinium Pharmaceuticals (ATNM), Nexvet Biopharma plc (NVET), CytRx (CYTR), Akari Therapeutics PLC (AKTX), Brainstorm Cell Therapeutics (BCLI), Synthetic Biologics (SYN), Cancer Genetics (CGIX), Transenterix (TRXC) and Sophiris Bio (SPHS).
Who owns ContraVir Pharmaceuticals stock?
ContraVir Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.22%), HighTower Advisors LLC (1.64%), Geode Capital Management LLC (0.56%), Morgan Stanley (0.44%), JPMorgan Chase & Co. (0.31%) and Prospera Financial Services Inc (0.28%). View Institutional Ownership Trends for ContraVir Pharmaceuticals.
Who sold ContraVir Pharmaceuticals stock? Who is selling ContraVir Pharmaceuticals stock?
Who bought ContraVir Pharmaceuticals stock? Who is buying ContraVir Pharmaceuticals stock?
How do I buy ContraVir Pharmaceuticals stock?
Shares of ContraVir Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of ContraVir Pharmaceuticals stock cost?
One share of ContraVir Pharmaceuticals stock can currently be purchased for approximately $0.67.
Earnings History for ContraVir Pharmaceuticals (NASDAQ:CTRV)Earnings History by Quarter for ContraVir Pharmaceuticals (NASDAQ:CTRV)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for ContraVir Pharmaceuticals (NASDAQ:CTRV)
Current Year EPS Consensus Estimate: $-0.41 EPS
Next Year EPS Consensus Estimate: $-0.37 EPS
Dividend History for ContraVir Pharmaceuticals (NASDAQ:CTRV)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for ContraVir Pharmaceuticals (NASDAQ:CTRV)
Insider Ownership Percentage: 3.30%Insider Trades by Quarter for ContraVir Pharmaceuticals (NASDAQ:CTRV)
Institutional Ownership Percentage: 5.49%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|2/18/2016||James Sapirstein||CEO||Buy||10,000||$1.00||$10,000.00|| |
|11/23/2015||James Sapirstein||CEO||Buy||2,500||$1.64||$4,100.00|| |
|3/4/2014||John P Brancaccio||Director||Buy||4,393||$1.49||$6,545.57|| |
Headline Trends for ContraVir Pharmaceuticals (NASDAQ:CTRV)
Latest Headlines for ContraVir Pharmaceuticals (NASDAQ:CTRV)
|Zacks: Brokerages Expect ContraVir Pharmaceuticals Inc (CTRV) Will Announce Earnings of -$0.09 Per Share|
www.americanbankingnews.com - May 15 at 10:00 AM
|ContraVir Pharmaceuticals Inc (CTRV) Short Interest Update|
www.americanbankingnews.com - May 10 at 7:20 AM
|ContraVir Pharma (CTRV) to Advance Second-Generation Formulation of TXL for Treatment of HBV - StreetInsider.com|
www.streetinsider.com - May 6 at 7:58 AM
|ContraVir to Advance Second-Generation Formulation of Tenofovir Exalidex (TXL™) for Treatment of Hepatitis B Virus (HBV)|
finance.yahoo.com - May 4 at 7:35 AM
|ContraVir Pharmaceuticals Announces Closing of Public Offering of Common Stock and Warrants|
finance.yahoo.com - May 2 at 7:34 PM
|ContraVir Pharmaceuticals (CTRV) Receives Daily Coverage Optimism Rating of -0.10|
www.americanbankingnews.com - May 2 at 12:56 PM
|ContraVir Pharmaceuticals (CTRV) Receiving Somewhat Favorable News Coverage, Report Finds|
www.americanbankingnews.com - April 28 at 10:26 AM
|ContraVir Pharmaceuticals (CTRV) Receiving Somewhat Positive Media Coverage, Study Shows|
www.americanbankingnews.com - April 25 at 7:26 PM
|Mid-Day Market Update: NASDAQ Hits 6,000; Heidrick & Struggles Shares Drop On Downbeat Results|
www.nasdaq.com - April 25 at 4:20 PM
|ContraVir Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Warrants|
finance.yahoo.com - April 25 at 11:58 AM
|ContraVir Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants|
finance.yahoo.com - April 24 at 4:27 PM
|Zacks: Brokerages Expect ContraVir Pharmaceuticals Inc (CTRV) Will Announce Earnings of -$0.14 Per Share|
www.americanbankingnews.com - April 24 at 12:45 PM
|ContraVir Pharma (CTRV) Presents Data on Complementary Anti-HBV Compounds Tenofovir Exalidex (TXL) & CRV431|
www.streetinsider.com - April 24 at 9:15 AM
|ContraVir Pharmaceuticals Inc (CTRV) Rating Reiterated by Noble Financial|
www.americanbankingnews.com - April 22 at 6:32 PM
|Data Enhances Understanding of ContraVir’s Complementary Anti-HBV Compounds Tenofovir Exalidex (TXL™) and CRV431|
finance.yahoo.com - April 22 at 4:23 PM
|ContraVir Pharmaceuticals (CTRV) Given Media Sentiment Rating of 0.41|
www.americanbankingnews.com - April 21 at 2:18 PM
|Oral Presentation at EASL Highlights ContraVir’s Tenofovir Exalidex (TXL™) Antiviral Activity in Hepatitis B (HBV) Patients|
finance.yahoo.com - April 20 at 4:43 PM
|ContraVir Pharmaceuticals (CTRV) Earns Daily Media Impact Rating of 0.56|
www.americanbankingnews.com - April 18 at 9:35 AM
|Maxim Group Analysts Give ContraVir Pharmaceuticals Inc (CTRV) a $4.00 Price Target|
www.americanbankingnews.com - April 17 at 10:50 AM
|Maxim Group Reiterates "$4.00" Price Target for ContraVir Pharmaceuticals Inc (CTRV)|
www.americanbankingnews.com - April 14 at 3:34 PM
|ContraVir Pharmaceuticals (CTRV) Earning Favorable News Coverage, Analysis Shows|
www.americanbankingnews.com - April 14 at 9:46 AM
|ContraVir to Highlight New Data at EASL The International Liver Congress™ 2017 in Amsterdam, The Netherlands|
finance.yahoo.com - April 11 at 1:00 PM
|ContraVir Pharmaceuticals Inc (CTRV) Given "Buy" Rating at Noble Financial|
www.americanbankingnews.com - April 8 at 8:04 AM
|Maxim Group Reaffirms Buy Rating for ContraVir Pharmaceuticals Inc (CTRV)|
www.americanbankingnews.com - April 4 at 1:23 PM
|ContraVir’s Cyclophilin Inhibitor CRV431 Targets Hepatitis B Surface Antigen (HBsAg)|
www.nasdaq.com - April 4 at 8:49 AM
|CONTRAVIR PHARMACEUTICALS, INC. Financials|
finance.yahoo.com - February 18 at 4:22 PM
|CONTRAVIR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report|
biz.yahoo.com - February 14 at 8:46 PM
|ContraVir to Highlight Clinical Data from Ongoing Phase 2a Study of Tenofovir Exalidex (TXL™) for Treating Hepatitis B|
finance.yahoo.com - February 14 at 3:46 PM
|ContraVir Pharmaceuticals to Present at BIO CEO & Investor Conference - PR Newswire (press release)|
www.prnewswire.com - February 7 at 10:44 PM
|ContraVir Pharmaceuticals to Present at BIO CEO & Investor Conference|
finance.yahoo.com - February 7 at 5:41 PM
|Technical Reports on Biotech Stocks -- ContraVir Pharma, Arena Pharma, Neuralstem, and CTI BioPharma|
www.bizjournals.com - January 17 at 5:25 PM
|Technical Reports on Biotech Stocks -- ContraVir Pharma, Arena Pharma, Neuralstem, and CTI BioPharma - PR Newswire (press release)|
www.prnewswire.com - January 17 at 8:39 AM
|ContraVir Pharmaceuticals to Present at Biotech Showcase 2017|
us.rd.yahoo.com - January 4 at 5:40 PM
|ContraVir Pharma (CTRV) Awarded ~$300K Canadian Research Grant|
www.streetinsider.com - January 4 at 4:14 AM
|ContraVir Pharma (CTRV) Awarded ~$300K Canadian Research ... - StreetInsider.com|
www.streetinsider.com - January 3 at 12:42 PM
|ContraVir Awarded Grant from Canada's National Research Council to Advance CRV431 for the Treatment of Hepatitis B|
finance.yahoo.com - January 3 at 12:42 PM
ContraVir Pharmaceuticals (CTRV) Chart for Thursday, May, 25, 2017